Cargando…

Design of PD-L1 inhibitors for lung cancer

The progression of lung cancer is associated with inactivation of programmed cell death protein 1, abbreviated as PD- 1 which regulates the suppression of the body's immune system by suppressing T- cell inflammatory activity and is responsible for preventing cancer cell growth. It is of interes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Udhwani, Trishang, Mukherjee, Sourav, Sharma, Khushboo, Sweta, Jajoriya, Khandekar, Natasha, Nayarisseri, Anuraj, Singh, Sanjeev Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Biomedical Informatics 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677907/ https://www.ncbi.nlm.nih.gov/pubmed/31435160 http://dx.doi.org/10.6026/97320630015139

Ejemplares similares

Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis
por: Jain, Divya, et al.
Publicado: (2019)

An In silico Approach to Identify High Affinity Small Molecule Targeting m-TOR Inhibitors for the Clinical Treatment of Breast Cancer
por: Patidar, Khushboo, et al.
Publicado: (2019)

FLT3 inhibitor design using molecular docking based virtual screening for acute myeloid leukemia
por: Gokhale, Padmini, et al.
Publicado: (2019)

Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia
por: Sweta, Jajoriya, et al.
Publicado: (2019)

Identification of Potent VEGF Inhibitors for the Clinical Treatment of Glioblastoma, A Virtual Screening Approach
por: Yadav, Mohini, et al.
Publicado: (2019)

Genome analysis of biosurfactant producing bacterium, Bacillus tequilensis
por: Nayarisseri, Anuraj, et al.
Publicado: (2023)

Virtual Screening of IL-6 Inhibitors for Idiopathic Arthritis
por: Shukla, Palak, et al.
Publicado: (2019)

Screening, isolation and characterization of biosurfactant producing Bacillus subtilis strain ANSKLAB03
por: Nayarisseri, Anuraj, et al.
Publicado: (2018)

Structural basis for the in vitro known acyl-depsipeptide 2 (ADEP2) inhibition to Clp 2 protease from Mycobacterium tuberculosis
por: Khandekar, Natasha, et al.
Publicado: (2016)

Screening, Purification and Characterization of Protease Inhibitor from Capsicum frutescens
por: Mohan, Manju, et al.
Publicado: (2018)

Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor
por: Bandaru, Srinivas, et al.
Publicado: (2017)

Molecular docking approaches in identification of High affinity inhibitors of Human SMO receptor
por: Akare, Uday Raj, et al.
Publicado: (2014)

Molecular docking based screening of GABA (A) receptor inhibitors from plant derivatives
por: Sahila, Mohammed Marunnan, et al.
Publicado: (2015)

Biodegradation effects of o-cresol by Pseudomonas monteilii SHY on mustard seed germination
por: Krishnan, Shainy Nhattuketty, et al.
Publicado: (2018)

Identification and characterization of cresol degrading Pseudomonas monteilii strain SHY from Soil samples
por: Krishnan, Shainy Nhattuketty, et al.
Publicado: (2018)

Common SAR Derived from Linear and Non-linear QSAR Studies on AChE Inhibitors used in the Treatment of Alzheimer’s Disease
por: Pulikkal, Babitha Pallikkara, et al.
Publicado: (2017)

Implications of a novel Pseudomonas species on low density polyethylene biodegradation: an in vitro to in silico approach
por: Bhatia, Mayuri, et al.
Publicado: (2014)

Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions
por: Nasr, Arash Boroumand, et al.
Publicado: (2015)

Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia
por: Marunnan, Sahila Mohammed, et al.
Publicado: (2017)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
por: Singh, Vishakha, et al.
Publicado: (2021)

EDITORIAL: Improving Neuropharmacology using Big Data, Machine Learning and Computational Algorithms
por: Shameer, Khader, et al.
Publicado: (2017)

Molecular Docking and Pharmacological Investigations of Rivastigmine-Fluoxetine and Coumarin–Tacrine hybrids against Acetyl Choline Esterase
por: Babitha, Pallikkara Pulikkal, et al.
Publicado: (2015)

Insights from the predicted epitope similarity between Mycobacterium tuberculosis virulent factors and its human homologs
por: Gutlapalli, Venkata Ravi, et al.
Publicado: (2015)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
por: Liu, Si-Yang, et al.
Publicado: (2017)

Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
por: Taoka, Masataka, et al.
Publicado: (2022)

Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition
por: Sinha, Chanda, et al.
Publicado: (2014)

Natural Bioactive Products with Antioxidant Properties Useful in Neurodegenerative Diseases
por: Mendonça-Junior, Francisco J. B., et al.
Publicado: (2019)

Computer aided identification of sodium channel blockers in the clinical treatment of epilepsy using molecular docking tools
por: Shaheen, Uzma, et al.
Publicado: (2015)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

The effect of gender on the clinical outcome of PD-1/PD-L1 inhibitor in advanced lung cancer patients
por: Wu, Bing, et al.
Publicado: (2023)

Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control
por: Sharma, Harsh, et al.
Publicado: (2023)

Natural Bioactive Products with Antioxidant Properties Useful in Neurodegenerative Diseases 2020
por: Mendonça-Junior, Francisco Jaime Bezerra, et al.
Publicado: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Kumar, Utpal, et al.
Publicado: (2021)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
por: Yao, W., et al.
Publicado: (2021)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
por: Dart, Sarah J., et al.
Publicado: (2021)

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bgkhaj6f1s209pkmsfu4o0n7d6